CTL019
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Lymphoblastic Leukemia
Conditions
Acute Lymphoblastic Leukemia
Trial Timeline
Apr 24, 2017 → Oct 13, 2020
NCT ID
NCT03123939About CTL019
CTL019 is a phase 3 stage product being developed by Novartis for Acute Lymphoblastic Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03123939. Target conditions include Acute Lymphoblastic Leukemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03601442 | Pre-clinical | Active |
| NCT04161118 | Phase 2 | Terminated |
| NCT04094311 | Phase 3 | Recruiting |
| NCT03876769 | Phase 2 | Active |
| NCT03123939 | Phase 3 | Completed |
| NCT02435849 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Lymphoblastic Leukemia